These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 6494246)
41. Software assessment under consideration of validation aspects: PPS and PMS systems. Arnold L; Frauch P; Klöti A; Staub M Pharm Acta Helv; 1998 Feb; 72(6):327-32. PubMed ID: 9556433 [TBL] [Abstract][Full Text] [Related]
42. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. Greenhill LL; Vitiello B; Abikoff H; Levine J; March JS; Riddle MA; Capasso L; Cooper TB; Davies M; Fisher P; Findling RL; Fried J; Labellarte MJ; McCracken JT; McMahon D; Robinson J; Skrobala A; Scahill L; Varipatis E; Walkup JT; Zito JM J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):651-5. PubMed ID: 12921472 [TBL] [Abstract][Full Text] [Related]
43. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
44. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
45. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise]. Ekimoto H Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236 [TBL] [Abstract][Full Text] [Related]
46. Phase IV research by pharmaceutical companies. Hakkarainen H; Hattab JR; Venulet J Pharmacopsychiatry; 1984 Sep; 17(5):168-75. PubMed ID: 6494246 [TBL] [Abstract][Full Text] [Related]
47. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
48. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
49. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe. Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456 [TBL] [Abstract][Full Text] [Related]
51. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
52. Analgesia and anesthesia for neonates: study design and ethical issues. Anand KJ; Aranda JV; Berde CB; Buckman S; Capparelli EV; Carlo WA; Hummel P; Lantos J; Johnston CC; Lehr VT; Lynn AM; Maxwell LG; Oberlander TF; Raju TN; Soriano SG; Taddio A; Walco GA Clin Ther; 2005 Jun; 27(6):814-43. PubMed ID: 16117988 [TBL] [Abstract][Full Text] [Related]
53. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process. Linden M Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512 [TBL] [Abstract][Full Text] [Related]
54. Issues in the design of clinical trials for safety in HIV-infected children. Lindsey JC; Kline MW Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484 [TBL] [Abstract][Full Text] [Related]